Scpharmaceuticals Inc (SCPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scpharmaceuticals Inc (SCPH) has a cash flow conversion efficiency ratio of 0.756x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.11 Million) by net assets ($-21.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scpharmaceuticals Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Scpharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Scpharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scpharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scpharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rimini Street Inc
NASDAQ:RMNI
|
-0.906x |
|
ACOTEC SCIEN.H. DL-00001
F:7W3
|
N/A |
|
D. Boral ARC Acquisition I Corp. Class A Ordinary Shares
NASDAQ:BCAR
|
-0.001x |
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
0.008x |
|
VT GMP Co.Ltd
KQ:018290
|
-0.043x |
|
ASYMCHEM LAB.(TIAN.)H YC1
F:7K90
|
N/A |
|
E Split Corp Class A
TO:ENS
|
0.100x |
|
T3EX Global Holdings Corp
TW:2636
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Scpharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Scpharmaceuticals Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see SCPH market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.32 Million | $-70.54 Million | -5.296x | -232.68% |
| 2023-12-31 | $37.22 Million | $-59.24 Million | -1.592x | -233.46% |
| 2022-12-31 | $72.43 Million | $-34.58 Million | -0.477x | +0.72% |
| 2021-12-31 | $56.47 Million | $-27.15 Million | -0.481x | -42.66% |
| 2020-12-31 | $82.17 Million | $-27.69 Million | -0.337x | +43.13% |
| 2019-12-31 | $51.37 Million | $-30.44 Million | -0.593x | -61.98% |
| 2018-12-31 | $78.74 Million | $-28.81 Million | -0.366x | -70.99% |
| 2017-12-31 | $106.00 Million | $-22.68 Million | -0.214x | -151.33% |
| 2016-12-31 | $-37.07 Million | $-15.46 Million | 0.417x | -21.12% |
| 2015-12-31 | $-18.24 Million | $-9.64 Million | 0.529x | -- |
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more